• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » eResearch Income Falls 63%

eResearch Income Falls 63%

July 31, 2009
CenterWatch Staff

Philadelphia-based eResearch Technology (ERT) reported second quarter financial results after the markets closed Thursday. Included in the results were ERT’s electronic data capture (EDC) operations, which were sold to Omnicomm Systems in June.

ERT’s second-quarter revenues were down 32% to $24.2 million, compared to $35.5 million a year ago. EDC licenses and service revenues accounted for $1.1 million of total revenue. The company reported a $500,000 gain on the sale of its EDC operations.

Net income for ERT was also down significantly over last year. Second quarter net income was $2.5 million, or $0.05 per diluted share, compared to $6.7 million, or $0.13 per diluted share a year ago.

 “Revenue and bookings continue to be significantly impacted by lower spending by clients on Thorough QT trials,” ERT president and CEO Michael McKelvey said in a statement. “Sponsors may delay the running of Thorough QT trials until later in the drug development cycle, though regulatory guidance ultimately requires that they be performed. As previously announced, we consolidated our customer care teams in Philadelphia and continue to improve the efficiency of our operations. This resulted in increases in our margins in the second quarter and will positively impact our cost base in the future. We believe the divestiture of our EDC operations will be positive for ERT as it allows us to focus our efforts on cardiac safety and ePRO opportunities."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing